JP6272626B2 - カンナビノイド受容体媒介性化合物 - Google Patents
カンナビノイド受容体媒介性化合物 Download PDFInfo
- Publication number
- JP6272626B2 JP6272626B2 JP2015542015A JP2015542015A JP6272626B2 JP 6272626 B2 JP6272626 B2 JP 6272626B2 JP 2015542015 A JP2015542015 A JP 2015542015A JP 2015542015 A JP2015542015 A JP 2015542015A JP 6272626 B2 JP6272626 B2 JP 6272626B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound
- acid
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(NC(N(CC1c2ccccc2)N=C1c(cc1)ccc1Cl)=NS(c(cc1)ccc1Cl)(=O)=O)=N Chemical compound *C(NC(N(CC1c2ccccc2)N=C1c(cc1)ccc1Cl)=NS(c(cc1)ccc1Cl)(=O)=O)=N 0.000 description 4
- BOJVWWCQFBGRMZ-UHFFFAOYSA-N CC(C)(C[AlH2])N/C(/N(CC1c2ccccc2)N=C1c(cc1)ccc1Cl)=N\S(c(cc1)ccc1Cl)(=O)=O Chemical compound CC(C)(C[AlH2])N/C(/N(CC1c2ccccc2)N=C1c(cc1)ccc1Cl)=N\S(c(cc1)ccc1Cl)(=O)=O BOJVWWCQFBGRMZ-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| US61/725,949 | 2012-11-13 | ||
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015536997A JP2015536997A (ja) | 2015-12-24 |
| JP2015536997A5 JP2015536997A5 (enExample) | 2016-12-28 |
| JP6272626B2 true JP6272626B2 (ja) | 2018-01-31 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015542015A Active JP6272626B2 (ja) | 2012-11-13 | 2013-11-12 | カンナビノイド受容体媒介性化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (enExample) |
| EP (1) | EP2919779B1 (enExample) |
| JP (1) | JP6272626B2 (enExample) |
| CN (1) | CN104884057B (enExample) |
| CA (1) | CA2889697C (enExample) |
| IN (1) | IN2015DN03733A (enExample) |
| WO (1) | WO2014078309A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2919779B1 (en) | 2012-11-13 | 2021-01-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| WO2015172059A1 (en) * | 2014-05-09 | 2015-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| EP3303325A1 (en) * | 2015-06-04 | 2018-04-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| EP3423448B1 (en) * | 2016-03-04 | 2024-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| US20230174493A1 (en) * | 2020-03-24 | 2023-06-08 | Inversago Pharma Inc. | Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors |
| CA3169745A1 (en) | 2020-04-07 | 2021-10-14 | Inversago Pharma Inc. | Process for producing 4,5-dihydro-1h-pyrazoles and intermediates |
| CN118829427A (zh) * | 2022-02-24 | 2024-10-22 | 诺和诺德股份有限公司 | 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法 |
| EP4493547A1 (en) * | 2022-03-14 | 2025-01-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor modulating compounds |
| WO2025257151A1 (en) | 2024-06-10 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating ciliopathies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| PL208098B1 (pl) * | 2000-03-23 | 2011-03-31 | Solvay Pharm Bv | Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposób wytwarzania związków oraz ich zastosowanie |
| CZ2003698A3 (cs) * | 2001-03-22 | 2003-06-18 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost |
| CN101659639A (zh) * | 2001-09-21 | 2010-03-03 | 索尔瓦药物有限公司 | 具有cb1-拮抗活性的新的4,5-二氢-1h-吡唑衍生物 |
| KR100950430B1 (ko) | 2001-09-21 | 2010-04-02 | 솔베이 파마슈티칼스 비. 브이 | 효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체 |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| EP1713475B1 (en) | 2004-01-30 | 2008-07-30 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| EP2023920B1 (en) | 2006-05-05 | 2012-06-13 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| CA2708706A1 (en) | 2007-12-10 | 2009-06-18 | 7Tm Pharma A/S | Cannabinoid receptor modulators |
| WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2012068529A2 (en) | 2010-11-18 | 2012-05-24 | Jenrin Discovery | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| EP2919779B1 (en) | 2012-11-13 | 2021-01-06 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| WO2015172059A1 (en) | 2014-05-09 | 2015-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| EP3303325A1 (en) | 2015-06-04 | 2018-04-11 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en not_active Ceased
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
-
2017
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2889697C (en) | 2023-03-14 |
| US9765031B2 (en) | 2017-09-19 |
| US10683270B2 (en) | 2020-06-16 |
| JP2015536997A (ja) | 2015-12-24 |
| US11939297B2 (en) | 2024-03-26 |
| US11485709B2 (en) | 2022-11-01 |
| US20230219896A1 (en) | 2023-07-13 |
| CA2889697A1 (en) | 2014-05-22 |
| EP2919779B1 (en) | 2021-01-06 |
| US20200331861A1 (en) | 2020-10-22 |
| EP2919779A1 (en) | 2015-09-23 |
| CN104884057A (zh) | 2015-09-02 |
| CN104884057B (zh) | 2019-08-20 |
| WO2014078309A8 (en) | 2015-05-21 |
| US20180022706A1 (en) | 2018-01-25 |
| WO2014078309A1 (en) | 2014-05-22 |
| US10787419B2 (en) | 2020-09-29 |
| US20230202983A1 (en) | 2023-06-29 |
| US20160039766A1 (en) | 2016-02-11 |
| IN2015DN03733A (enExample) | 2015-09-18 |
| US20180022705A1 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11939297B2 (en) | Cannabinoid receptor mediating compounds | |
| US20190352268A1 (en) | Cannabinoid receptor mediating compounds | |
| JP6564380B2 (ja) | 前立腺癌を治療するための化合物 | |
| AU2019227889B2 (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators | |
| BRPI0611853A2 (pt) | derivados de n-(piridin-2-il)-sulfonamida | |
| US11155521B2 (en) | Cannabinoid receptor mediating compounds | |
| EP3423448B1 (en) | Cannabinoid receptor mediating compounds | |
| TW201302736A (zh) | 組織蛋白酶（Ｃａｔｈｅｐｓｉｎ）Ｃ抑制劑 | |
| JP6906444B2 (ja) | 疾患および状態を処置するための組成物および方法 | |
| US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
| HK1232213B (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161111 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170817 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171230 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6272626 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |